RESUMO
The aim of this study was to screen potential myelotoxicity of the emerging mycotoxins Beauvericin, Enniatin b and Moniliformin using human hematopoietic progenitor clonogenic assays. Depending on mycotoxins, inhibitory effects on proliferation of white blood cells progenitors (CFU-GM), platelet progenitors (CFU-MK) and red blood cells progenitors (BFU-E) have been detected at various concentrations. Beauvericin was cytotoxic at 32µM, 3.2µM and 6.4µM, had no effect on proliferation in the presence of 0.032µM, 0.16µM and 0.064µM, and the IC(50) was equal to 3.4µM, 0.7µM and 3.7µM for CFU-GM, CFU-MK and BFU-E, respectively. Enniatin b was cytotoxic at 6µM, 1.8µM and 5µM, had no effect on proliferation in the presence of 1µM, 1.1µM and 1.2µM and the IC(50) was equal to 4.4µM, 1.3µM and 3.3µM for CFU-GM, CFU-MK and BFU-E, respectively. Moniliformin was not cytotoxic at tested concentrations for CFU-GM and CFU-MK and cytotoxic at 10µM for BFU-E, had no effect on proliferation in the presence of 5µM, 0.1µM and 0.1µM and the IC(50) was equal to 31µM, 39µM and 4.1µM for CFU-GM, CFU-MK and BFU-E, respectively. Inhibition of the BFU-E differentiation has been observed in the presence of Enniatin b or Moniliformin. For the three mycotoxins, variation of distribution of CFU-MK colonies according to their size has been observed. These in vitro effects may be responsible for in vivo hematological troubles in case of consumption of contaminated commodities. In vivo studies have to be performed to test this hypothesis.